To explore the potential of PD-1/PD-L1 blockade in combination with other therapies to achieve a functional cure in chronic hepatitis B (CHB) patients.
Approach:
Overview of Chronic Hepatitis B: Chronic hepatitis B affects 260 million people globally, with current therapies focusing on viral suppression but lacking in achieving functional cures. Limitations of these therapies include the need for long-term treatment and the inability to eliminate viral reservoirs.
Mechanism of PD-1/PD-L1 Blockade: The PD-1/PD-L1 pathway contributes to T-cell exhaustion in CHB, limiting the immune system’s ability to clear HBV. Its blockade may reinvigorate antiviral T-cell responses.
Clinical Trials and Findings: Early clinical trials indicate that PD-1/PD-L1 inhibitors can significantly reduce HBsAg levels, with some patients achieving functional cure, particularly those with low baseline HBsAg levels. These findings are preliminary and require further validation.
Combination with Pegylated Interferon: Combining PD-1/PD-L1 inhibitors with pegylated interferon has shown enhanced effects, achieving a functional cure rate of 30% in ongoing research.
Key Findings:
PD-1/PD-L1 inhibitors can significantly reduce HBsAg levels in CHB patients.
A subset of patients has achieved functional cure, particularly those with low baseline HBsAg levels.
Combination therapies with pegylated interferon enhance the functional cure rate.
Interpretation:
The findings suggest that PD-1/PD-L1 blockade, particularly in combination with other therapies, may provide a pathway to achieving functional cures in CHB.
Limitations:
Challenges include optimizing dosing regimens and selecting appropriate patients.
Identifying predictors of response and managing immune-related adverse events remain unresolved.
Conclusion:
Future large-scale randomized controlled trials are necessary to evaluate the efficacy and safety of PD-1/PD-L1 blockade in CHB.
